Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma

Eble, 2004, Pathology and genetics of tumours of the urinary system and male genital organs Stoter, 1987, Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder, J Urol, 137, 663, 10.1016/S0022-5347(17)44168-1 Wu, 2005, Urothelial tumorigenesis: a tale of divergent pathways, Nat Rev Cancer, 5, 713, 10.1038/nrc1697 Saxman, 1997, Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study, J Clin Oncol, 15, 2564, 10.1200/JCO.1997.15.7.2564 Sternberg, 2007, Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer, Urology, 69, 62, 10.1016/j.urology.2006.10.041 Gildea, 2004, PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity, Oncogene, 23, 6788, 10.1038/sj.onc.1207599 Atkins, 2004, Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma, J Clin Oncol, 22, 909, 10.1200/JCO.2004.08.185 Chan, 2005, Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer, J Clin Oncol, 23, 5314, 10.1200/JCO.2005.66.130 Drakos, 2008, Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas, Expert Rev Mol Med, 10, e4, 10.1017/S1462399408000586 Hay, 2005, The Akt-mTOR tango and its relevance to cancer, Cancer Cell, 8, 179, 10.1016/j.ccr.2005.08.008 Sabatini, 2006, mTOR and cancer: insights into a complex relationship, Nat Rev Cancer, 6, 729, 10.1038/nrc1974 Hanna, 2008, mTOR pathway in renal cell carcinoma, Expert Rev Anticancer Ther, 8, 283, 10.1586/14737140.8.2.283 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Nocito, 2001, Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade, J Pathol, 94, 349, 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D Mutter, 2000, Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers, J Natl Cancer Inst, 92, 924, 10.1093/jnci/92.11.924 Liaw, 1997, Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome, Nat Genet, 16, 64, 10.1038/ng0597-64 Birle, 2006, Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts, Mol Cancer Ther, 5, 2494, 10.1158/1535-7163.MCT-05-0504 Altomare, 2004, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth, Oncogene, 23, 5853, 10.1038/sj.onc.1207721 Chiang, 2005, Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase, J Biol Chem, 280, 25485, 10.1074/jbc.M501707200 Shor, 2008, A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis, Cancer Res, 68, 2934, 10.1158/0008-5472.CAN-07-6487 Liu, 2000, Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens, Mol Carcinog, 29, 143, 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A Aveyard, 1999, Somatic mutation of PTEN in bladder carcinoma, Br J Cancer, 80, 904, 10.1038/sj.bjc.6690439 Sarbassov, 2006, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB, Mol Cell, 22, 159, 10.1016/j.molcel.2006.03.029 Scholzen, 2000, The Ki-67 protein: from the known and the unknown, J Cell Physiol, 182, 311, 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 Granville, 2006, Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway, Clin Cancer Res, 12, 679, 10.1158/1078-0432.CCR-05-1654 Podsypanina, 2001, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice, Proc Natl Acad Sci U S A, 98, 10320, 10.1073/pnas.171060098 Cappellen, 1997, Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder, Oncogene, 14, 3059, 10.1038/sj.onc.1201154 Qian, 2009, Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models, Cancer Res, 69, 8256, 10.1158/0008-5472.CAN-09-1689 Puzio-Kuter, 2009, Inactivation of p53 and Pten promotes invasive bladder cancer, Genes Dev, 23, 675, 10.1101/gad.1772909 Pymar, 2008, Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms, Hum Mol Genet, 17, 2006, 10.1093/hmg/ddn098 Cairns, 1993, Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9, Oncogene, 8, 1083 Hashimoto, 2008, Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells, Eur J Cancer, 44, 1022, 10.1016/j.ejca.2008.02.043 Lamouille, 2007, Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway, J Cell Biol, 178, 437, 10.1083/jcb.200611146 Faried, 2006, Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy, Oncol Rep, 16, 57 Fechner, 2009, Rapamycin inhibits in vitro growth and release of angiogenic factors in human bladder cancer, J Urol, 73, 665, 10.1016/j.urology.2008.09.070 Wouters, 2008, Hypoxia signalling through mTOR and the unfolded protein response in cancer, Nat Rev Cancer, 8, 851, 10.1038/nrc2501 Arsham, 2003, A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets, J Biol Chem, 278, 29655, 10.1074/jbc.M212770200 Li, 2007, Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb, J Biol Chem, 282, 35803, 10.1074/jbc.M705231200